SureTrader SureTrader SureTrader
Home > Boards > US OTC > Biotechs >

Innovus Pharmaceuticals, Inc. (INNV)

Add INNV Price Alert      Hide Sticky   Hide Intro
Moderator: BooDog, kkpennies, Honeycomb777, jump3mb, Peter Lynch
Search This Board:
Last Post: 1/20/2017 1:18:00 PM - Followers: 100 - Board type: Free - Posts Today: 0
shareholders, please consider purchasing product(s)

***  ALERT ***

Awaiting Official Announcement of FDA Approval for FlutiCare

FlutiCare Approval could bring a BILLION DOLLARS in sales annually

REDONDO BEACH, CA--(Marketwired - Jul 12, 2016) -, a leading financial news and information portal offering free real time public company filing alerts, discusses the potential impact of the anticipated FDA ruling on Innovus Pharmaceuticals' (OTCQB: INNV) ANDA filing for FlutiCare™, the company's over-the-counter treatment for allergic rhinitis.

FlutiCare™ is designed to treat non-allergic rhinitis -- better known as "hay fever" or "stuffy nose" -- which affects roughly 50 million Americans each year. While 70% of these individuals use over-the-counter products, more than half are not satisfied with the treatment option, according to an Asthma and Allergy Foundation of America survey, which suggests there's an opportunity for a prescription-strength OTC treatment option to capture market share from category leaders.

As the #1 prescription nasal steroid with over 177 million units sold since 2007, Innovus believes that the over-the-counter version of FlutiCare™ could be worth up to $1 billion per year by addressing a much wider over-the-counter market. The FDA decision is expected in the next several weeks.


The CEO has already signed an agreement for the manufacturing of FlutiCare

Innovus Pharma Achieves Major Milestone With Securing a Manufacturing Agreement for FlutiCare in Anticipation of the FDA Decision

SAN DIEGO, CA--(Marketwired - May 31, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced that it signed a manufacturing agreement for the supply of its FlutiCare™ 60 and 120 spray/bottles.  Innovus signed the agreement in anticipation of the FDA's decision, expected between July-September of this year, on the ANDA application for the drug.


Prior to joining Innovus Pharma,

Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. 
where he helped move the company's stock price from
19 Cents to $6.00 !!!
(Uplisted from OTC to NASDAQ)


Company Profile:

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

Business Summary:

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The company?s pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was incorporated in 2011 and is based in San Diego, California.

Bassam Damaj, Ph.D.
President and Chief Executive Officer:

Dr. Bassam Damaj was appointed to serve as our President and Chief Executive Officer in January 2013. Prior to joining Innovus Pharma, Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company, from December 2009 until November 2012. At Apricus Bio, Dr. Damaj was responsible for the approval of its lead drug Vitaros, a treatment for erectile dysfunction. Dr. Damaj also signed multimillion dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda. Before Apricus Bio, Dr. Damaj was a co-founder of Bio-Quant, Inc. and served as the Chief Executive Officer and Chief Scientific Officer and a Director of Bio-Quant's board of directors from its inception in June 2000 until its acquisition by Apricus Biosciences in December 2009. In addition, Dr. Damaj was the founder, Chairman, President and Chief Executive Officer of R&D Healthcare, and the co-founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was a Member of the Scientific Advisory Board of MicroIslet, Inc. He is the author of the Immunological Reagents and Solutions reference book, the inventor of many patents and author of numerous peer reviewed scientific publications. Dr. Damaj won a US Congressional award for the Anthrax Multiplex Diagnostic Test in 2003. Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in molecular oncology from McGill University.


Robert E. Hoffman
Executive Vice President and Chief Financial Officer:

Mr. Hoffman was appointed as our Executive Vice President and Chief Financial Officer on September 6, 2016. Prior to Innovus Pharma, Mr. Hoffman was Chief Financial Officer of AnaptysBio, Inc., a clinical stage biopharmaceutical company. He was part of the founding management team of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), a biopharmaceutical company, in 1997, serving as Senior Vice President, Finance and Chief Financial Officer until 2015. He also served as Chief Financial Officer for Polaris Group, a biopharmaceutical drug company, from March 2011 to August 2011. Mr. Hoffman is a member of the board of directors of CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company, Kura Oncology, Inc. (NASDAQ:KURA), a biotechnology company, and MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX), a biopharmaceutical company. He also was a member of the Financial Accounting Standards Board’s Small Business Advisory Committee until 2015 and is a member of the steering committee of the Association of Bioscience Financial Officers. Mr. Hoffman received his B.B.A. from St. Bonaventure University, and is licensed as a C.P.A. (inactive) in the State of California.


Who are the major players at Innovus Pharma?


Share Structure:

Shares Outstanding:     ~ 122 Million (as of 1/6/17)   Dr. Damaj owns $23+M shares alone

- Current cash on-hand is enough to fund operations through Q3 of 2017.  Profitability expected around that time !
- 2017 Projected Revenue of $15M (NOT counting FlutiCare), which would be approximately 3x GREATER than 2016. 


Company Videos:

Innovus Pharma CEO Provides Shareholder Update and Conference Call

Corporate Presentation November 2016 (8-K  11/1/2016)

Upcoming PDUFA and ANDA Approval Dates Could Catalyze Innovus Pharma (INNV) and Lipocine (LPCN)

Innovus Pharma (INNV): Targeting $3+ Billion Markets With 13 Commercial Products

Major 2016 Accomplishments:



Where can INNV products be seen?


Existing Product Lines @ Innovus Pharma:

Are you looking to boost your brain health?r

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
INNV News: Initial Statement of Beneficial Ownership (3) 01/09/2017 07:01:06 AM
INNV News: Statement of Changes in Beneficial Ownership (4) 01/09/2017 06:05:10 AM
INNV News: Statement of Changes in Beneficial Ownership (4) 01/09/2017 06:05:10 AM
INNV News: Statement of Changes in Beneficial Ownership (4) 01/09/2017 06:05:10 AM
INNV News: Current Report Filing (8-k) 01/06/2017 04:13:17 PM
#4539  Sticky Note Innovus Pharma Signs $2 Million a Year Exclusive BooDog 11/29/16 06:49:09 AM
#4406  Sticky Note Proven revenue & cash positive potential for 2017. BooDog 11/17/16 06:00:40 AM
#2422  Sticky Note For anyone willing/wondering about how they can HELP Honeycomb777 08/13/16 11:27:51 AM
#5165   kk- You are correct but I still believe ShawnP123 01/20/17 01:18:00 PM
#5164   I think there are traders that are heavily kkpennies 01/20/17 12:00:06 PM
#5163   kk- unfortunately charts, etc. have little bearing as ShawnP123 01/20/17 11:58:16 AM
#5162   Wow, not very good on the bids. Looks ShawnP123 01/19/17 04:07:34 PM
#5161   Williams %R Check on Shares of Innovus Pharmaceuticals kkpennies 01/19/17 12:49:11 PM
#5160   I don't want to be his age (86) Batermere 01/18/17 08:44:52 PM
#5159   Thats why you just an ihub poster and Adrock 01/18/17 07:56:01 PM
#5158   Not really. It peaked at .66. I left Batermere 01/18/17 07:55:20 PM
#5157   You da man! Buy low sell high, your a Adrock 01/18/17 07:48:58 PM
#5156   I sold at .60 and bought back at Batermere 01/18/17 06:58:12 PM
#5155   I'm a sucker the stock is down from .60 Adrock 01/18/17 06:53:42 PM
#5153   ,, DOG BARKING , BUT CARAVAN GOES ,, healthywelth 01/18/17 04:15:58 PM
#5152   For a guy that is short, your bad futurebeaneater 01/18/17 02:52:20 PM
#5151   I've got the sinking feeling of bad news Adrock 01/18/17 02:06:18 PM
#5150   its quiet, too quiet Peter Lynch 01/18/17 01:05:13 PM
#5149   Still here - just chilling during the quiet Honeycomb777 01/18/17 12:12:04 PM
#5148   Honey job is done year, sorry to those Adrock 01/18/17 11:13:20 AM
#5146   Where is Honey? COACH14 01/18/17 10:16:55 AM
#5145   I am impressed that it moved EXACTLY like PersianMeow 01/16/17 07:21:13 PM
#5144   I'm really impressed with INNV's stability today, I'm gi197845 01/16/17 02:45:27 PM
#5143   Bullish Peter Lynch 01/15/17 09:49:46 PM
#5142   I was taught early in life by a Adrock 01/14/17 08:07:10 AM
#5139   Adrock, it was a joke and even if gi197845 01/13/17 03:35:36 PM
#5138   Peter Lynch, it was a joke and even gi197845 01/13/17 03:34:30 PM
#5137   ShawnP123, it was a joke and even if gi197845 01/13/17 03:33:50 PM
#5136   where did you see this, if you dont Peter Lynch 01/13/17 03:32:42 PM
#5135   Can you post this for us please! Thanks from Adrock 01/13/17 03:12:32 PM
#5134   Where did you see that? If true, it ShawnP123 01/13/17 03:09:29 PM
#5133   Damn! ANDA paperwork filing error! Now we're gonna gi197845 01/13/17 03:00:27 PM
#5132   Lmao...Adrock aka incontinence, doesn't understand the space time theruleoflaw 01/13/17 02:38:58 PM
#5131   Totally possible and a very cool story if true. PersianMeow 01/12/17 06:11:50 PM
#5130   my humble understanding of the .95 pricing was futurebeaneater 01/12/17 06:00:54 PM
#5129   For everyone's reading enjoyment about the psychology of pricing! PersianMeow 01/12/17 05:11:08 PM
#5128   Hey guys ADROCK back in the hub, Adrock 01/12/17 01:51:38 PM
#5127   4 cents spread... jbdiver 01/12/17 01:14:22 PM
#5126   wow....17??? i am all in... Q4 should come TRUMPFORPRES 01/12/17 01:04:49 PM
#5125   Looks like NITE, CANT, & ETRF did nothing ShawnP123 01/12/17 12:52:41 PM
#5124   Nothing BobbyB2222 01/12/17 10:22:00 AM
#5123   I disagree.... No consumer is going to reject Honeycomb777 01/12/17 09:59:47 AM
#5122   Honeycomb, no one can take that .04 cent Peter Lynch 01/12/17 09:24:36 AM
#5121   Hey Bassam - why not make ALL of Honeycomb777 01/11/17 09:23:39 PM
#5120   probably just a move up to higher highs Peter Lynch 01/11/17 09:02:12 PM
#5119   Grasping at straws...So it can be manipulated on sweetstreet 01/11/17 09:01:18 PM
#5118   Ladies don't get your panties in a bunch Adrock 01/11/17 08:37:13 PM
#5117   Yes the god father of the short syndicate jbdiver 01/11/17 07:01:09 PM
#5116   AdRock...Haven't seen him since this thing went green, sweetstreet 01/11/17 05:58:42 PM
#5115   .01c a day x 20 days a mo mike007 01/11/17 10:58:54 AM
#5114   One way to find out is to contact ShawnP123 01/10/17 08:51:22 PM
#5113   I read this completely different. In Pazzo1212 01/10/17 08:36:05 PM
#5112   No, innovus owns the rights to fluticare, we Peter Lynch 01/10/17 08:23:05 PM